Your browser doesn't support javascript.
loading
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
Llibre, Josep M; López Cortés, Luis Fernando; Aylott, Alicia; Wynne, Brian; Matthews, Jessica; Van Solingen-Ristea, Rodica; Vandermeulen, Kati; van Wyk, Jean; Kahl, Lesley P.
Afiliação
  • Llibre JM; Infectious Diseases, Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
  • López Cortés LF; Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Aylott A; Biostatistics, GlaxoSmithKline, Brentford, United Kingdom.
  • Wynne B; Medicines Development, ViiV Healthcare, Research Triangle Park, NC.
  • Matthews J; Clinical Development, ViiV Healthcare, Research Triangle Park, NC.
  • Van Solingen-Ristea R; Clinical Development, Janssen Research and Development, Beerse, Belgium.
  • Vandermeulen K; Global Regulatory and Compound Development, Janssen Research and Development, Beerse, Belgium.
  • van Wyk J; Global Medical, ViiV Healthcare, Brentford, United Kingdom; and.
  • Kahl LP; Clinical Development, ViiV Healthcare, Brentford, United Kingdom.
J Acquir Immune Defic Syndr ; 91(1): 73-78, 2022 09 01.
Article em En | MEDLINE | ID: mdl-35551149
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Aterosclerose Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Aterosclerose Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article